Clinical trials: Bacillus-Calmette-Guerin
Tuberculosis
Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK Adults
TB043 is a clinical challenge trial primarily to evaluate the safety of BCG challenge administered by the aerosol inhaled route in healthy, BCG naive (Group 1-7) as well as historically BCG vaccinated UK adults (Group 8) .
- Trial name
- NCT03912207
- Testing
- BCG Danish
- Where
- 2 sites in United Kingdom
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Non Muscle Invasive Bladder Cancer
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
The purpose of this study is to determine whether Nanoxel®M is effective in the treatment of patients with recurrent Ta and T1 who experienced treatment failure with at least one prior BCG intravesical treatment.
- Trial name
- NCT02982395
- Testing
- Nanoxel®M, Mitomycin-C
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Tuberculosis
A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG
A new, more specific skin test to detect tuberculosis has been developed by Statens Serum Institut in Denmark. The new skin test is named C-Tb and like the current Tuberculin a positive test result will show as redness and/or…
- Trial name
- TESEC-03 (NCT01242475)
- Testing
- C-Tb, 2 TU Tuberculin PPD RT 23 SSI
- Where
- United Kingdom
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Bladder Cancer
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to test the safety of avelumab and Bacille Calmette-Guerin (BCG) and see what effects (good and bad) that this combination treatment has on subjects with recurrent bladder cancer.
- Trial name
- OU-SCC-ABC (NCT03892642)
- Testing
- Avelumab, BCG
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Oklahoma
Bladder Cancer
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
The investigators aim to investigate a possible role for radiotherapy in good prognosis bladder cancer patients has been identified as a possible alternative to cystectomy, especially for patients non-eligible for surgery but has…
- Trial name
- NCT06310369
- Testing
- radiation therapy
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01118351
- Testing
- sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Urinary Tract Urothelial Carcinoma
Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
A majority of patients with bladder cancer have disease confined to the inner lining of the bladder. Patients with high risk features (high grade tumors, tumors invading into a deeper superficial layer) are routinely treated with…
- Trial name
- Sutent (NCT00794950)
- Testing
- Sunitinib
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan
Bladder Cancer
AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from…
- Trial name
- NCT00003759
- Testing
- BCG vaccine, valrubicin, conventional surgery
- Where
- United States
- Sponsor
- Anthra Pharmaceuticals
Tuberculosis
A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination
This is a human pilot study of 16 healthy BCG-naïve volunteers to quantify BCG from the BCG vaccination site. Volunteers will be vaccinated with BCG.
- Trial name
- NCT00653627
- Testing
- BCG
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Allergy, Eczema
Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction
1. To determine if BCG immunisation at birth, compared to no BCG immunisation, leads to a reduction in measures of allergy and infection in the first 12 months of life. 2.
- Conditions
- Allergy, Eczema, Respiratory Tract Infections
- Trial name
- MIS BAIR (NCT01906853)
- Testing
- BCG
- Where
- 2 sites in Australia
- Volunteers
- 1,272 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Trained Immunity, BCG Vaccine
BCG-induced Epigenetic Modifications in the NEXT Generation
Non-specific protective effects resulting from the BCG vaccine appear to be paternally inheritable. Since the BCG vaccine is known to induce trained immunity, epigenetics might explain the fathers' contribution to the immune…
- Conditions
- Trained Immunity, BCG Vaccine, Epigenetics
- Trial name
- NEXT (NCT05766345)
- Testing
- BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
COVID-19
BCG Vaccination to Prevent COVID-19
The current COVID-19 epidemic threatens to overwhelm the capacity of many countries to meet their populations' health care needs.
- Trial name
- NUEVA (NCT04632537)
- Testing
- Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine, Preservative-free saline
- Volunteers
- healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Urinary Bladder Neoplasms
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
- Trial name
- CheckMate 9UT (NCT03519256)
- Testing
- Nivolumab, BCG, BMS-986205
- Where
- 88 sites in United States, Argentina and 13 more
- Volunteers
- 142 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
In this study, the investigators would like to assess how intravesical BCG schedules after immunization of non muscle invasive bladder patients with the recMAGE-A3 protein, together with adjuvant AS15 (recMAGE-A3 + AS15 ASCI)…
- Trial name
- NCT01498172
- Testing
- MAGE-A3 ASCI, BCG
- Where
- Switzerland
- Volunteers
- 23 people
- Sponsor
- Patrice Jichlinski
Safety, Immunogenicity
EMaBS TB Vaccine Study
The study will commence with a dose-escalation and age de-escalation study in healthy adults and adolescents from the previous Entebbe Mother and Baby Study (EMaBS) in Entebbe, Uganda, focusing on ChAdOx1 85A, to provide safety…
- Trial name
- NCT03681860
- Testing
- ChAdOx185A, MVA85A, BCG
- Where
- 2 sites in Uganda, United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Multiple Sclerosis
Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis
The frequency of auto-immune diseases (including multiple sclerosis) is increasing in industrialised countries. According to an hypothesis which is receiving a wide international credit, this may be due to the fact that the…
- Trial name
- NCT00202410
- Testing
- Bacille of Calmette-Guerin
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- S. Andrea Hospital
Bladder Cancer
Biomarker Discovery and Application in Bladder Cancer
The investigators' long-term objective is to research and develop innovative new tests which diagnostic laboratories can use to 1) detect methylated DNA targets, 2) tumor specific antigens, and 3) markers of Bacillus…
- Trial name
- NCT00962052
- Where
- Israel
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Wolfson Medical Center
Latent Tuberculosis Bacteriology and Histology Unknown, Latent Tuberculosis
A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)
This is a Phase I/IIa, double-blind, randomized, placebo-controlled, dose- and regimen-finding study in healthy adults with and without LTBI, who are BCG-vaccinated, HIV negative, and have no history or evidence of TB disease.
- Trial name
- NCT01865487
- Testing
- H56ug/IC31nmol
- Where
- 2 sites in South Africa
- Volunteers
- 98 people
- Sponsor
- Aeras
COVID-19
The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines
Clinical trial with randomized allocation in two arms (BCG vaccine versus placebo) of volunteers at risk but not yet infected nor vaccinated against SARS-CoV-2.
- Trial name
- SARS-CoV-2 (NCT05507671)
- Testing
- BCG (Bacillus Calmette-Guérin) vaccine
- Where
- 4 sites in Brazil
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Innate Immune Response
A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study
Neonatal morbidity and mortality from infectious diseases is of global concern. Childhood disease-specific immunisation is irrefutably linked to the decline in deaths from these targeted infections over the last century.
- Trial name
- ELVIS (NCT02444611)
- Testing
- BCG Vaccine, Hepatitis B Vaccine
- Where
- Australia
- Volunteers
- 185 people
- Sponsor
- Murdoch Childrens Research Institute